The Tumor Treating Fields Market to Exhibit Strong Growth owing to Rising Prevalence of Cancer

The tumor treating fields market comprises electric field-based medical devices used in cancer treatment. Tumor treating fields therapy uses alternating electric fields to disrupt cancer cell division and proliferation. It works by interfering with normal cell division activities such as alignment and movement of internal cell structures called mitotic spindles. This disrupts the orderly process by which normal healthy cells divide and grow, resulting in cancer cell death. Tumor treating fields are delivered through non-invasive transducer arrays placed on the patient's skin. They enable the delivery of low-intensity and intermediate frequency alternating electric fields to the tumor region. The therapy provides additional therapy option as adjuvant treatment for recurrent glioblastoma and mesothelioma.

Key Takeaways

Key players operating in the Tumor Treating Fields Market Size are Tier 1 Companies (DS Smith PLC, Crown Holdings Inc., Ardagh Group, WestRock Co., Owens-Illinois Inc., International Paper Company Inc., Amcor PLC, Delta Global, GPA Global), and Tier 2 Companies (HH Deluxe Packaging, Prestige Packaging Industries, Pendragon Presentation Packaging, Stolzle Glass Group, Keenpac, Elegant Packaging, BC Boncor, Luxpac Ltd, McLaren Packaging Ltd, and B Smith Packaging Ltd). The companies are investing in new product development and expansion strategies to strengthen their market position.

The increasing prevalence of cancer worldwide presents considerable opportunities for tumor treating fields therapy adoption. Factors such as better outcomes with tumor treating fields adjuvant therapy for glioblastoma, approval for additional cancer indications, and ongoing clinical trials assessing efficacy in other cancers are expected to drive the market growth.

The major players are focused on expanding their geographic presence globally. For instance, Novocure is establishing reimbursement pathways and clinical access programs across Europe, Asia Pacific, and Latin America to commercialize Optune for additional cancer types like pancreatic cancer.

Market Drivers
Rising prevalence of cancer worldwide is a major factor augmenting the demand for tumor treating fields therapy. According to Globe Cancer, cancer burden is expected to grow to 27.5 million new cases and 16.3 million cancer deaths by 2040. Additionally, growing geriatric population prone to cancer also drives the market growth. For example, in 2040, one in every six people globally will be over age 65.

Market Restraints
High cost of tumor treating fields devices and therapy is identified as a major challenge restricting market penetration in price-sensitive regions. Optune device alone costs over $20,000 per month of treatment. Additional monthly costs are incurred for transducer arrays. Such high treatment costs pose affordability issues for a section of the population in developing countries.

Segment Analysis
The tumor treating fields market is dominated by the Glioblastoma segment. Glioblastoma is the most common and aggressive type of primary brain tumor in humans. It accounts for about 15% of all primary brain tumors and close to 54% of all gliomas diagnosed. Glioblastomas are Grade IV astrocytomas which mean they are fast-growing and highly invasive. Due to the aggressiveness and lethality of glioblastomas, tumor treating fields therapy has emerged as a standard treatment option for newly diagnosed as well as recurrent glioblastoma. This has predominantly driven the growth of the glioblastoma segment in the tumor treating fields market.

Global Analysis
Regionally, North America commanded the largest share in the tumor treating fields market in 2024 owing to advanced healthcare facilities, favorable reimbursements for tumor treating fields therapy, and presence of prominent players in the region. The Asia Pacific region is anticipated to witness the highest growth during the forecast period driven by growing incidences of brain cancers and economic growth of countries like China and India enabling greater access to advanced tumor treatment options. Stringent regulations and pricing pressures in Europe may hamper the market growth to some extent. However, advantages of tumor treating fields therapy over chemotherapy are likely to drive its adoption across major countries.

Get More Insights On This Topic: Tumor Treating Fields Market